Domača stranMEHCQ • OTCMKTS
add
23andMe Holding Co.
Prejšnji trg. dan.
1,17 $
Dnevni razpon
1,07 $ - 1,18 $
Letni razpon
0,48 $ - 12,76 $
Tržna kapitalizacija
30,85 mio. USD
Povprečni obseg
8,09 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
OTCMKTS
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(USD) | dec. 2024info | Sprememba L/L |
---|---|---|
Prihodek | 60,26 mio. | 34,67 % |
Stroški poslovanja | 65,06 mio. | −22,18 % |
Čisti dohodek | −53,04 mio. | 80,92 % |
Čista dobičkovnost prihodkov | −88,01 | 85,83 % |
Earnings per share | — | — |
EBITDA | −21,80 mio. | 62,70 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
(USD) | dec. 2024info | Sprememba L/L |
---|---|---|
Denar. in kratkor. naložbe | 79,35 mio. | −67,27 % |
Skupna sredstva | 277,42 mio. | −54,39 % |
Skupne obveznosti | 214,70 mio. | −7,06 % |
Celoten lastniški kapital | 62,72 mio. | — |
Shares outstanding | 26,83 mio. | — |
Razmerje P/B | 0,50 | — |
Donosnost sredstev | −21,15 % | — |
Donosnost kapitala | −42,49 % | — |
Denarni tok
Neto sprememba denarnih sredstev
(USD) | dec. 2024info | Sprememba L/L |
---|---|---|
Čisti dohodek | −53,04 mio. | 80,92 % |
Denar iz dejavnosti | −44,65 mio. | −270,23 % |
Denar iz naložb | 887,00 tis. | 144,09 % |
Denar iz financiranja | −19,00 tis. | −118,10 % |
Neto sprememba denarnih sredstev | −43,79 mio. | −213,47 % |
Prost denarni tok | −20,18 mio. | −469,10 % |
Vizitka
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Datum ustanovitve
apr. 2006
Sedež organizacije
Spletno mesto
Zaposleni
571